KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPensionPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

West Pharmaceutical Services (WST) Retained Earnings (2016 - 2025)

Historic Retained Earnings for West Pharmaceutical Services (WST) over the last 17 years, with Q3 2025 value amounting to $4.3 billion.

  • West Pharmaceutical Services' Retained Earnings rose 1051.36% to $4.3 billion in Q3 2025 from the same period last year, while for Sep 2025 it was $4.3 billion, marking a year-over-year increase of 1051.36%. This contributed to the annual value of $4.0 billion for FY2024, which is 1229.49% up from last year.
  • West Pharmaceutical Services' Retained Earnings amounted to $4.3 billion in Q3 2025, which was up 1051.36% from $4.1 billion recorded in Q2 2025.
  • Over the past 5 years, West Pharmaceutical Services' Retained Earnings peaked at $4.3 billion during Q3 2025, and registered a low of $2.0 billion during Q1 2021.
  • Its 5-year average for Retained Earnings is $3.2 billion, with a median of $3.3 billion in 2023.
  • In the last 5 years, West Pharmaceutical Services' Retained Earnings skyrocketed by 3303.19% in 2021 and then soared by 1051.36% in 2025.
  • Over the past 5 years, West Pharmaceutical Services' Retained Earnings (Quarter) stood at $2.5 billion in 2021, then increased by 21.62% to $3.0 billion in 2022, then rose by 17.93% to $3.5 billion in 2023, then increased by 12.29% to $4.0 billion in 2024, then grew by 7.73% to $4.3 billion in 2025.
  • Its last three reported values are $4.3 billion in Q3 2025, $4.1 billion for Q2 2025, and $4.0 billion during Q1 2025.